Volume 4, Issue 3, 2026

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

DECODING THE ROLE OF PROBIOTICS IN INFANT HEALTH: INSIGHTS FROM CLINICAL AND EXPERIMENTAL EVIDENCE

Muhammad Hamza[*1], Nayyab Naqvi[2], Kishmala Shahid[3], Ayesha Siddiqua[4], Muhammad Imran[5]

[*1]*Department of Food Science, Government College University Faisalabad, Faisalabad, Pakistan*
[2]*Emergency Medicine Trainee, Pakistan Ordinance Factory Hospital, Wah Cantt, Rawalpindi, Punjab, Pakistan*
[3]*Department of Nutritional Sciences, Government College University Faisalabad, Faisalabad, Pakistan*
[4]*Department of Food Science, Government College University Faisalabad, Faisalabad, Pakistan*
[5]*UIMLT, The University of Lahore, Pakistan*

[*1]mh0410829@gmail.com, [2]nayyabnaqvi22@gmail.com, [3]kashmalashahid623@gmail.com, [4]ayeshasaddiqua634@gmail.com, [5]hafizimran1745@gmail.com

ORCID: [*1]0009-0004-5746-1526, [3]0009-0003-4211-214X, [4]0009-0002-5774-5890, [5]0009-0003-4251-5280

DOI: https://doi.org/10.5281/zenodo.22121416

Keywords
Human milk oligosaccharides (HMOs), probiotics, prebiotics, gut microbiota, infant health.

Article History
Received: 30 January 2026
Accepted: 15 March 2026
Published: 31 March 2026

Copyright @Author
Corresponding Author: *
Muhammad Hamza

Abstract

Infancy is a critical time for the inception of gut microbiota, which is essential for long- term development, immunological maturation, and infant health. Probiotic therapies have been clinically proven to promote digestive health and defense against dysbiosis-related illnesses by regulating microbial composition, elevating microbial diversity, and lowering possibly pathogenic bacteria, particularly with strains like bifidobacterium and lactobacillus. Probiotics can strengthen gastrointestinal function, ease constipation, minimize the risk of infections, and reduce the frequency of acute necrotizing enterocolitics (NEC) in premature newborns, based on clinical findings. Additionally, probiotics, prebiotics, and synbiotics have been related to reduce prevalence of atopic dermatitis, and allergic sensitization during pregnancy and early life period, emphasizing their role in immunological programming. Despite outcomes in human, are still inconclusive, emerging findings also highlight potential gains on cognitive and neurodevelopmental results via regulation of gut-brain exist. In conclusion, additionally probiotics, synbiotics, or human milk oligosaccharides (HMOs) to baby formulae has confirmed potential for encouraging balanced gut colonization and partially mimicking the protective advantages of breastfeeding. Overall, these outcomes emphasize the diverse effects of probiotics across early life stages, covering gut health, immunology, prevention of allergic conditions, cognitive maturation, and nutritional support, establishing them crucial tactic for enhancing early-life health outcomes.

INTRODUCTION

The formation and maturation of gut micro bio, which is necessary for immune system formation, sustained health, and overall infant well-being, is critical throughout early life stages (He et al., 2024). Since birth, infants gut microbial community changes constantly due to a variety of circumstances, containing gestational age, mode of delivery, type of feeding, antibiotic exposure, and environmental conditions in neonatal care. Premature baby is especially vulnerable to severe conditions like necrotizing enter colitis (NEC),

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

delayed sepsis, and other immune-mediated disorders due to postponed colonization by beneficial obligate, anaerobes and an elevated incidence of potentially pathogenic bacteria (Aveline et al., 2026).

To modulate gut colonization profile and recover microbial equilibrium in infancy. Probiotics live-microorganism that delivers health gains when given in adequate quantity has turn into essential tactic (Ennis et al., 2024). Supplementing with particular strains, particularly bifid bacterium and lactobacillus species, can enhance microbial variety, support gut barrier activity, reduce gastrointestinal disturbance like constipation, and minimize risk of infection, as indicated by clinical and preclinical findings (Feng et al., 2025). Furthermore, probiotics improves overall gastrointestinal resilience and can lower severe NEC in preterm child.

Apart from digestive health, probiotics, prebiotics, symbiotic are crucial for early immunological programing due to relationship among the immune system and gut bacteria .when provided during the gestational period or neonatal stage, there is proof that these therapies can minimize the risk of atopic dermatitis, allergy sensitization, and other atopy related disorders (More et al., 2021).When integrated with bifidobacterial strains that can metabolize them human milk oligosaccharides (HMOs) additionally enhance the development of a healthy gut micro biota, stimulating some of the beneficial effects of nursing.

Whereas there are still few and sometimes contradictory human studies, emerging research also propose that probiotics may enhance neurodevelopment and cognitive effects by regulating the gut-brain axis. Therefore, the administration of probiotics, prebiotics, symbiotic, and HMO fortified formulae represents multimodal approach to improve early life, including immune function, gut micro biota profile, allergy prevention, neurodevelopment and nutritional support (Talat et al., 2025).

Collectively, the combination of these interventions highlights their crucial role in promoting infant health throughout highly malleable developmental window, supplying a promising why to elevate lifelong outcomes, assist optimal growth, and enhance resistance versus disease. In order to clarify the pathways of action, clinical significance, and potential for influencing early-life health trends of probiotics, prebiotics, and HMO therapies, this review critically evaluates the available data (Hojsak et al., 2026).

1. Literature Review

1.1 Microbial Foundations of Early Life

Immune development, metabolic programming, and sustained health are all affected by the important biological process of gut microbiota development during infancy. By 2.5-3 years of age, the low-diversity microbial community in an early-life infant gut has developed into a more-established, adult like ecosystem, mostly as results of supplemental nutrition and the cessation of breastfeeding (Bäckhed et al., 2015). Based on recent findings, these are three phases of development: a transitional phase characterized by baceriodates and proteobacteria, a later stabilizing phase dominated by firmicutes and anaerobic communities, and an initial phase dominated by bifidobacteria.

Mode of delivery, feeding pattern, gestational age, interaction with antibiotics, and the neonatal environment all affect microbiota development. Babies that have breastfed generally have higher quantity of lactobacillus and bifidobacterium, in contrast formula-fed babies have more potentially pathogenic taxa but more microbial diversity. Preterm newborn infant is more vulnerable to necrotizing enterocolitis (NEC) and sepsis because of decreased variety and greater colonization by hospital-associated microorganisms.

1.2 Microbiota Modulation Strategies

Live bacteria recognized as probiotic are advantageous to health when consumed in adequate quantity. Because they are naturally prevalent in healthy breastfed infants, bifidobacterium and lactobacillus are the most investigated strains in infant health. Prebiotic are non-digestible substrates that promote the growth of beneficial microorganisms, while synbiotics incorporate probiotics with prebiotics to strengthen colonization and function.

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

The third most common solid element of human milk, human milk oligosaccharides (HMOs), particularly bifidobacterium longum subsp. Infantis (Kiely et al., 2023). These therapeutic approaches are not just dietary supplements; they are microbiota-directed approaches.

1.3 Mechanistic Insights into Probiotic Action

Probiotics have situation specific and strain-specific impacts. Their pathways include immunological modulation, gut barrier integrity enhancement, synthesis of beneficial metabolites like short-chain fatty acids (SCFAs), and ecological competition with pathogens. SCFAs like lactate and acetate promote epithelial tight junctions, lower gut PH, prevent pathogens, and enhance metabolic balance (Maghsoumi-Norouzabad et al., 2025).

Furthermore, probiotics control immunity by regulating–cell balance, secretory immunoglobulin A (IgA), dendritic cells, and cytokine. Research indicates that, bifidobacteria improve immunological imprinting and reduce inflammatory signals throughout infancy (Henrick et al., 2021).

1.4 Clinical Translation and Health Outcomes

Probiotic utilization in premature newborn is significantly supported by clinical findings to prevent NEC. Probiotics interaction within the first 14 days significantly decreased serious NEC, late-onset sepsis, and mortality, based on large population-based trial enrolling 48,048 infants born before 32-week gastation. Furthermore, mea-analysis shows a significant modification of the microbiome with elevated lactobaccilus and bifidobacterium and decreased pathogenic taxa. Probiotics may reduce colic, bowel irregularity, and gastrointestinal pain in term newborns, although their advantages are more variable (Indrio et al., 2022).

1.5 Immune Imprinting and Allergy Modulation

Moreover, immunological programming and allergy prevention are supported by probiotics, prebiotics, and synbiotics. Atopic dermatitis and aczema are most significantly decreased when prenatal supplementation are introduced throughout the third trimester and continued postnatally, particularly with mixed-strain formulations. However, there is still contradictory data about the prevention of allergic rhinitis.

1.6 Neurodevelopmental Implications of the Gut–Brain Axis

Based on recent findings, probiotics may be associated to neurodevelopment via gut-brain axis. SCFA signaling, tryptophan metabolism modulation, decreased neuroinflammation, and optimized blood-brain barrier function are some of the proposed mechanisms. Although preclinical study points to advantageous impacts on memory and cognition, there is still inconsistence findings and scant human evidence (Marano et al., 2025).

1.7 Advanced Nutritional Biotherapeutics

The advantageous impacts of breastfeeding maybe partially repeated in formula-fed infants by HMO-enriched and symbiotic compositions. According to clinical findings probiotics and 2'-fucosyllactose (2'-FL)-containing formulations improve microbial composition, reduce respiratory infections, and stimulate healthy growth (Alliet et al., 2022). However, the complex biological composition of breast milk cannot be entirely replicated by these compositions.

1.8 Knowledge Gaps and Future Perspectives

Probiotics, prebiotics, synbiotics, and HMOs play different but supporting functions in promoting infant health; their advantages are highly context dependent, emphasizing the need for accuracy microbiota-directed therapies. Despite increasing evidence critical knowledge gaps remain regarding strain-specific effects, dose optimization, mechanistic pathways, and long-term neurodevelopmental results (Jankiewicz et al., 2023).

2. Methodology

The published scientific literature on probiotics, prebiotics, synbiotics, and human milk oligosaccharides (HMOs) and their impacts on baby health were examined narratively in this study. Four electronic databases were used for an extensive literature search: PubMed, Scopus, Web

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

of Science, and Google Scholar. To integrate both essential and modern material, the search was performed in April 2026 with an eligibility window that reviewed article from January 2015 to April 2026.

Using Boolean operators (AND, OR), the following search terms were used both individually and in combination: "probiotics", "prebiotics," "synbiotics," "human milk oligosaccharides," "gut microbiota," "infant health," "necrotizing enterocolitis," "preterm infant," "allergy prevention," "immune programming," "gut-brain axis," and neurodevelopment." To identify relevant sources that were undetected by database searches, the reference list of every article that was identified were further manually examined.

The predefined criteria were achieved by all included studies: (1) Published in peer-reviewed English-language journals; (2) Addressed on human infant or pediatric populations or presented preclinical data precisely clinically related to infants health; (3) Evaluated the impact of probiotics, prebiotics, synbiotics, or HMOs on gut microbiota formulation, therapeutic outcomes, immune functions, allergy prevention, or neurodevelopment; and (4) Reflected systematic reviews, meta-analyses, randomized controlled trials, cohort studies, or high quality narrative reviews. Studies that investigated only adult populations without data significant to infants, lacked precisely defined outcome assessed, or were published in non-peer reviewed publications were all omitted (Tarracchini et al., 2024).

The lead reviewer identified the studies and collects the data; cases that were uncertain were reassessed in light of the eligibility requirement. The AMSTAR-2 checklist was used to assess the methodological quality of the included systematic reviews and meta-analyses, and the SANRA (scale for assessment of narrative review articles) criteria were used to assess the narrative reviews. Omitted from integration were studies that did not achieve a minimum quality level to these instruments.

After full-text review and quality assessment, 14 sources in all were kept. Only articles offering direct mechanistic, clinical, or translational data relevant to the defined review areas were retained; this figure represent the application of strict eligibility and quality standards instead of extensive inclusion. Six pre-established domains-gut microbiota development, probiotic mechanisms, clinical outcomes, allergy and immunological programming, neurodevelopment, and nutritional biotherapeutics were used to narratively synthesize and thematically arrange the extracted material. Rather of being formulated empirically from the data, themes were predefined based on the field's current conceptual framework.

3. Analysis and Discussion

3.1 Development of gut microbiota

3.1.1 Overview of early life colonization and maturation

In infancy, the development of intestinal barrier and mucosal immune system and metabolic signaling processes all happens alongside with the growth of microbiota, which is a highly controlled biological mechanism, microbial colonization is better recognized to be an essential growth event that effect susceptibility to infection, allergic disease and inflammatory disorder and may affect neural growth rather than a passive result of birth. Based on long term research, the new born microbiome changes from a low diversity ecosystem immediately after birth to a more stable adult like community by the time and child is 2.5 to 3 years old, breastfeeding cessation and complementary feeding play an important function in transition, as illustrated in figure 1 (Ma et al., 2024).

3.1.2 Developmental phase and functional metabolic transitions

This mechanism can be clearly defined in terms of growth stage. According to recent findings, bifidobacteria prevail in early life stage, bacteroidetes and proteobacteria become common during transition stage, firmicutes and more sophisticated anaerobic communities are enriched during the later stabilization stage (Figure 1). The infant's gut changing nutritional environment is reflected in this pattern. Bifidobacteria particularly infant-adapted strains capable of HMO metabolism, are specifically favored by the amount of human milk oligosaccharides (HMOs)

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

in breastfed new born, following weaning, a larger community of microorganisms that use carbohydrates is promoted by the introduction of substrates derived from plants and starch. Therefore, microbiota maturation involves a functional shift from milk-oriented metabolism to more diverse fermentative environment rather than just systematic succession (Tanaka & Nakayama, 2017).

3.1.3 Key determinants: mode of delivery and feeding type and prematurity

This pattern is significantly affected by the number of infant factors. The major determinants and clinical significance are summarized in Table 1. Among the earliest and mostly reliable influences is mode of delivery. Whereas cesarean-delivered babies show a slow transfer of maternal anaerobes and comparatively higher abundance of skin and hospital acquired organism, vaginally born infants usually obtained germ linked to the mother's vaginal and intestinal microbiota. Supporting the hypothesis that the mode of delivery effects both composition and microbial ecosystem, Bäckhed et al. (2015) showed the newborn infant by cesarean section had gut microbiota composition that were less similar to those of their mothers than infants delivered vaginally. The method of feeding has similar impact formula-fed newborns often show higher microbial diversity earlier, with comparatively larger patterns of bacteroides, while breastfed infants usually harbor greater abundance of bifidobacteria and *Lactobacteria clostridia*. Enterobacteriaceae and other taxa more typical of later-life microbiomes (Inchingolo et al., 2024). These determinant-specific microbial pattern and associated clinical implications are summarized in Table 1 (Suárez-Martínez et al., 2023). A greater deviation from normal colonization is introduces by premature infants Preterm infants had reduced alpha-diversity and extended exposure to antibiotics , a higher risk of cesarean delivery, slowed requisition of essential anaerobes, and constant contact with neonatal critical care unit as compared to term babies this enhance the prevalence of opportunistic taxa like staphylococcus, enterobacteriaceae, enterococcus, and other microbes that have implemented to hospitals because they are linked with an elevated risk of necrotizing enterocolitis (NEC), late onset sepsis, and inflammatory instability ,these microbial structure are clinically significant. Thus, the preterm gut is especially appealing target for probiotics intervention because it is both a vulnerable host niche and a dysbiotic ecosystem.

3.1.4 Privileged Role of Infant-Type Bifidobacteria

Bifidobacteria have a unique role in the growth model. their importance stems from both here in the amount and there purpose HMOs are metabolized by infants type bifidobacteria , which also reduce luminal PH, generate lactate and acetate involves in cross feeding networks and create environmental that suppress the growth of pathogens.by indicating that breastfeeding associated bifidobacteria produce aromatic lactic acids and other metabolites with immunomodulatory potential ,latest studies has expended on this idea and suggested that "healthy colonization" involves specific metabolic outputs rather than just species presence (Laursen et al., 2021).

When integrated these results deliver proof for two key conclusions that are essential to your review. First the growth of microbiota in early stages of life is flexible and significant. Second, the biologically best composition observed in healthy, breastfed, full-term infants enriched in bifidobacteria are biologically suitable metabolites in a more pertinent comparator for any approach than a general "normal microbiota". For this reason, instead of being independent nutritional supplements, probiotics, prebiotics, synbiotics, and HMO-fortified formulas should be discussed as microbiota-directed developmental strategies.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Table 1: key determinants and clinical significance of infant gut microbiota development

Determinants	Effects on microbiota	Common Pattern	Clinical Importance
Mode of delivery	Shapes first colonization	Vaginal birth= Maternal microbes; C-section= delayed anaerobes	Dysbiosis risk in C-Section
Feeding type	Alters dominant taxa	Breast feeding=bifidobacteria Formula= Mixed flora	Immune and gut health
Pre maturity	Reduces diversity	Hospital-associated organisms increase	NEC and sepsis risk
HMOs exposure	Selective microbial feeding	Promotes infant-type *bifidobacteria*	Healthy colonization

Note: HMOs, Human milk oligosaccharides; NEC, *Necrotizing enterocoliti*




Figure 1: developmental stages of infant gut microbiome from birth to early childhood

3.2 Mechanism of probiotics

3.2.1 Overview of strains-specific and context-dependent action

Probiotics biological impacts on infants are complicated and cannot be summarized as "good bacteria replacing bad bacteria". The strains employed, the host gut's ecological setting, the availability of substrate, and the timing of injection all effect how they work. Ecological competition is a main mechanism. Probiotic has ability to inhabit adhesion sites, compete for nutrients, and alter the gut's physiochemical environment in ways that limit the development of potentially harmful microbes. Ecological reshaping is one off the most stable microbial effects across cohorts, as probiotics supplementation has been connected to consistent enrichment of bifidobacteria and lactobacillus and reduction of taxa like Klebsiella, Veillonella, and finegoldia in preterm infants (Liu & Yang, 2023).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

3.2.2 Metabolite production and trophic network stabilization

The formation of metabolites is a second essential process. Non digestible substrates are metabolized by bifidobacteria and lactobacilli to make short-chain fatty acids (SCFAs) especially lactate and acetate, which produce gut PH and inhibit the growth of PH-sensitive pathogens. Moreover, these metabolites function as signaling molecules. Acetate supports in cross feeding with secondary fermenters that create butyrate, improves tight-junction stability, and supports epithelial energy metabolism (Sjælland et al., 2025). Infant-type bifidobacteria function as major degraders in a trophic network, producing compounds that maintain the larger microbial ecology. This metabolic activity is especially important in the gut of breastfed infants, where HMOs offer specific strains like bifidobacterium longum subsp. Infantis a selective substrate. Furthermore, probiotics enhance the function of the host barrier (Bogaert et al., 2023). They may enhance mucus production, maintain tight-junction architecture, decrease intestinal permeability, and lessen inflammatory epithelium damage, based on experimental and clinical studies. Due to the anatomical and functional immaturity of the gut barrier in preterm infants, these results are particularly significant. The defensive signal observed for NEC and systemic infection may be partially explained by a better barrier which decrease bacterial translocation. Furthermore, reduced pro-inflammatory pathobiont level maintains the epithelial interface and reduces mucosal immune activation (Brasiel & Luquetti, 2025).

3.2.3 Immune modulation and inflammatory tone regulation

Another essential process is immune regulations. Through their effect on dendritic cells, secretory IgA, cytokine patterns, regulatory T –cell, and the Th1/Th2 stability, probiotics affect both innate and adaptive immunity. One of the most important recent studies found that supplementing with *B. infantis* EVC001 was associated with lower intestinal Th2-and Th17-associated inflammatory signaling, while lack of bifidobacteria and lower HMO utilization ability in early life associated to immune imbalance and systematic inflammation (Ho et al., 2018). The idea that probiotic-driven microbial recovery can change the inflammatory level of the infant gut is further supported by the related clinical study that demonstrated colonization with *B. infantis* EVC001 in exclusively breastfed infants decreased fecal calprotectin and pro-inflammatory cytokines. Finally, the gut brain axis is one of the distal signaling routes the regulate some probiotics effects. Probiotics may affect brain growth and stress responsiveness via altering tryptophan metabolism, SEFA synthesis, immunological signaling, and vagal or endocrine pathways (Sal-Sarria & Burnet, 2025). But in babies, this process is more recognized physiologically than clinically. Therefore, reviewer-level interpretation is that probiotic mechanisms are probable, complex, and becoming better understood; however, clinical translation is still more strong for intestinal and immunological results than for neurodevelopmental endpoints (Davis et al., 2022).

3.3 Method of administration

3.3.1 Routes of administration, Timing, and biological targets

One of the primary factors influencing efficacy in early life is the method and timing of probiotic delivery. According to the literature, Probiotics have been delivered through direct oral administration to the new born, internal administration in neonatal units, maternal supplementation during late pregnancy, and addition into infant formula as probiotic or symbiotic products. Because they interfere at different stages of microbiota assembly and may impact colonization directly through infant gut interaction or indirectly through maternal microbial transmission and immune programming, these methods are not biologically equivalent. In studies on allergic disease prevention, maternal prenatal additives are particularly important (Wang et al., 2025). Prenatal immune priming and early microbial delivery may be essential because trials that begin in the third trimester and last through the first few

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

months of an infant's life seem to be more effective in eliminating eczema than postnatal-only approaches. In contrast, if the primary objective is to prevent preterm intestinal morbidity or modulate gut microbiota, infant-only therapy might be adequate. This divergence is important because the biological attention is different: direct neonatal treatment targets ecological reconfiguration of the new born gut, while prenatal-postnatal application targets maternal-fetal and early immune development (Selma-Royo et al., 2024).

3.3.2 Enternal Administration in Neonatal Intensive Care and Safety Prerequisites

Probiotic are usually given internally in neonatal intensive care settings once limited meals are initiated. Because it interacts with feeding methods and permits administration during the window when dysbiosis is happening, this approach is clinically possible. According to preterm studies, early contact, frequently during first few days of two weeks of life, is associated to the most obvious benefits for NEC-related outcomes. But compared to population supplementing, new born use necessitates more stringent regulation. Important factor contains the product's identity, viable cell count, lack of transferable antimicrobial resistance, manufacturing quality, storage conditions, and the ability of local laboratories to detect probiotics sepsis. The ESPGHAN position document stressed that security requirements must be achieved prior to wide spread implementation in preterm units and only offered conditional recommendations for specific strains (van den Akker et al., 2020).

3.3.3 Formula Fortification, Synbiotic Design, and clinical Context Selection

Because formula-based delivery accommodates regular feeding routines and allows extended exposure, it is theoretically appealing. However, direct medicinal-style probiotic dosage and formula supplementation should not be used interchangeably. Probiotic or symbiotic-fortified formula trails reveal variation in strains, dosage, matrix composition, and background prebiotic content all of which can impact efficacy. Moreover, when the additional strains are biologically suitable to the nutrient in the formula, especially HMOs or HMO-like substrates, formula supplementation may be most efficient. Thus, symbiotic designs which combine a probiotic with its favored substrates are becoming more common than empirical combinations (Sharif et al., 2023).

From a comparative view, the clinical question decides the optimal path. Early internal neonatal administration has the best explanation for preventing preterm NEC. Combined nutrition for mothers and infants is more scientifically plausible for inhibiting allergies. Formula fortification with probiotics, synbiotics, or HMOs may offer a feasible but less strictly controlled option for healthy term infants who are not breastfed. The fundamental tenet of these approaches is that administration should be context-adapted, time-sensitive, and strains-specific rather than general (Szajewska et al., 2023).

3.4 Clinical Outcomes: NEC, Sepsis, and Gastrointestinal Disorders

3.4.1 preterm NEC Prevention: strongest clinical and mechanistic Evidence

Preterm newborn outcomes: especially NEC, have the powerful proof among all the suggested benefits of early life probiotics. The comparative strength of evidence across major clinical outcomes is summarized in Table 2 (Aceti et al., 2015). The pathophysiology of NEC, one of the most severe consequences of prematurity, is tightly linked with delayed microbial maturation, immature epithelial cells, heightened inflammatory reactions, and intestinal prevalence by opportunistic bacteria. Preterm newborn is now the population in which probiotic therapy is most thoroughly studied since the probiotics precisely aimed several of these routes.

The clinical case is strengthened by recent findings. Aviline and colleagues examined 48,048 infants born before 32 weeks of pregnancy in the larger tendency-matched population study from England and Wales. They discovered that probiotic interaction during the first 14 days of life was associated with the lower incidence of critical NEC is matched analysis (3.3% versus 4.2%; OR

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

0.80,95%CI0.72-0.89). One of the strongest real-world examples of how microbiota-focused treatment can result in significant newborn benefits is the same trails, which is also showed lower late-onset sepsis and increased survival until discharge. These findings support the classification of NEC prevention as the most established probiotic-associated clinical benefits in preterm infants, as summarized in Table 2. These clinical results are consistent with mechanistic microbiome evidence (Dai et al., 2025). According to meta-analysis probiotics regularly increased lactobacilli and bifidobacteria while decreasing potentially harmful taxa in preterm newborn across various populations, considerably, the scientist also identified functional alterations in the microbiome, such as a lower in heme formation pathways and an increase in peptidoglycan biosynthesis pathways. This suggest that probiotics appear to change the structure and functional ability of the microbial community in ways that plausibly lower the chance of disease instead of just including temporary species to feces. Further proof that ecological fitness in the infants is just as important as minimal formulations content comes from the results that bifidobacteria frequently become dominant even when mixed strains preparation contains equivalent dosage of lactobacilli (Zhou et al., 2023).

3.4.2 Sepsis outcomes: nuanced interpretation and evidence Hierarchy

The outcomes of sepsis are more sophisticated than those of NEC. This evidence hierarchy across neonatal outcomes is outlined in Table 2. Depending on the definition and strains employed, meta-analysis and observational studies frequently indicate either a minimal benefits or no meaningful impact on late onset-sepsis. This variation is important: although bloodstream infection is reliant on more general clinical factors like catheter use, respiratory support, and antibiotic procedures. NEC maybe more immediately controllable through local gut ecology and barrier impacts. However, when tolerability necessities are upheld, the lack of significant sepsis penalty in modern cohorts is comforting (Calvo et al., 2024). As reported by the authors, the empirical data hierarchy is therefore highest for NEC reduction, relatively weaker but still supportive for results related to sepsis, and reliant on the standard of the product and the environment of the deployment. In addition to preterm, probiotics have been examined for a variety of newborn gastrointestinal condition, including colic, functional constipation, antibiotic associated diarrhea, and nonspecific gastrointestinal discomfort. Here, the profile become less stable and more strains specific. The network mea analysis of formulas fortified with probiotics and symbiotic in well-nourished infant and young child showed evidence that some formulations reduced antibiotic use, days with fewer, and colic episodes (Wang et al., 2023). However, it is demonstrated meaningful heterogeneity and found no stable changes in major fecal bacterial groups or strong impacts on development across trials. Because targeted metabolic and physiological impacts may be more considerable than crude taxonomic prevalence, this suggest that clinical advantages may appear even in case when broad community-level stool readouts do not demonstrate a significant shift.

Another area that is gaining focus is constipation. Recent evidence shows, probiotics may improve the regularity and stability of stools by enhancing the formation of SCFA, lowering luminal PH, controlling gut motility, reducing low grade inflammation, and interacting with the enteric nervous system. However, variable strains selection, varied objectives, and small research continue to inhibit this field. Thus, the best way to describe constipation in newborn and young child is as a possible but unstandardized sign for probiotic therapy. creating general treatment claims is not as systematically sound as this stable framing. Careful analysis of the findings is also important for results related to diarrhea. The 2023 ESPGHAN position paper clearly states that suggestions are strain-specific and regularly rated as weak due to limited certainty, but it does support specific for a number of pediatric gastrointestinal disorders, Such as acute gastroenteritis and protection of antibiotic associated diarrhea. This is essential issue for your

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

review: advantageous results from a single strains and formulation unable to applied to all probiotic products. Thus, instead of relying solely on the generic term "probiotics" the clinical value of probiotics in gastrointestinal illness needs on aligned the indication to the strains backed by randomized human data (Vaz et al., 2024).

Overall, a tiered assessment is confirmed by clinical proof. Probiotic efficiency is intermediate for certain gastrointestinal signs like colic and potentially constipation, highly reliant on strains profile for diarrhea related indications, and maximum and most clinically significant in preterm NEC prevention. Journal reviewer determine this graded viewpoint more compelling than generic claims of broad gastrointestinal benefits.

Table 2: Summary of clinical outcomes, target populations, and strength of evidence for infant health intervention

Clinical outcomes	Evidence strength	Main population	Interpretation
NEC Prevention	Strong	Preterm infant	Most established benefits
Late onset sepsis	Moderate	Preterm infant	Supportive but variable
Colic/ constipation	Moderate	Term Infants	Symptoms-specific benefits
Neurodevelopment	Emerging	Infant/preterm	Promising but inconclusive

3.5 Allergy Prevention and Immune Programming

3.5.1 Clinical evidence of allergy prevention

One of the widely discussed about topics in early life microbiome study is the relationship between probiotics and the avoidance of allergy disease, on the other hand the proof is outcome specific rather than commonly protective. Atopic dermatitis and eczema have indicated the most stable impact. According to More et al.'s comprehensive analysis, eczema incidence is more reliable reduced by probiotic treatment initiating in the third trimester and ongoing during the first three to six month of life, especially when mixed strain preparations were given at dose of 10^9_10^10 colony forming unit (CFU)/day, as summarized in table 3. Alternatively, there was much inconsistent data for the protection of extensive allergy sensitization and allergic respiratory illness, as shown in Table 3 (Fijan et al., 2023). This analysis is enhanced by more recent findings. Probiotics did not considerably lower allergic rhinitis at any age, according to Xiao et al.'s 2025 meta-analysis, although they did lower atopic hypersensitivity in children older than one year, as presented in Table 3. Subgroups with longer approaches durations and those receiving combinations prenatal and postnatal supplements benefited more. This variation is important. According to Xiao et al. (2025), probiotics may impact upstream immune programming or sensitization pathways without inevitably avoiding all downstream allergy phenotypes, particularly complicated respiratory results like allergic rhinitis

Table 3: clinical efficacy and interpretation analysis of probiotics regimens on infant allergic phenotypes

Allergy Outcome	Probiotic Regimen	Reported Clinical Effect	Clinical Interpretation & Notes

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Atopic Dermatitis / Eczema	• Initiated in 3rd trimester • Continued 3–6 months postnatally • Mixed-strain preparations • Dose: 10^9–10^{10} CFU/day	Significant & reliable reduction	Most consistently supported outcome across meta-analyses. Benefit is strongest with combined prenatal.
Allergic Sensitization / Atopic Hypersensitivity	• Combined prenatal + postnatal supplementation • Extended treatment duration	Reduced atopic hypersensitivity	Suggests probiotics modulate upstream immune programming
Allergic Respiratory Illness / Allergic Rhinitis	Same regimens as above	No significant reduction	Complex downstream phenotype. Early microbial exposure may alter sensitization.

3.5.2 Mechanism Basis of Immune Modulation

These outcomes make biological interpretation from a mechanistic perspective. Initial colonization with lactobacilli and bifidobacteria enhances secretory IgA, modifies dendritic cell communication, promotes regulation T-cell growth, and skin in Th1/Th2 axis rebalancing. Moreover, pro allergic inflammatory response may be reduced and epithelial integrity strengthens by microbial metabolites such acetate and aromatic lactic acids. Henrick et al. shown that while breastfeeding-associated bifidobacteria and their metabolites may enhance improved immune imprinting, bifidobacterial loss in early infancy is associated with immunological imbalance. This offer is robust mechanistic association between the structure of the microbiota and the risk of allergies (Husein-ElAhmed, 2023).

3.5.3 Overall Scientific Interpretation

Hence, based on the evidence summarized in Table 3, it is not suitable to defined probiotics as general approach of "allergy prevention" according to a publication-strength conclusion. It would be more suitable to say that for allergic rhinitis and other respiratory allergic results is contradictory, perinatal probiotic therapies show their most compelling signal for minimizing eczema and may have a minimal effect on allergic sensitization. This subtlety enhances reviewer confidence and methodological rigor (Wang et al., 2025).

3.6 Gut-Brain axis and Neurodevelopment

3.6.1 Conceptual framework of the Gut-brain Axis

By associating intestinal microbial ecology with neuroimmune signaling, endocrine modulation, neurotransmitter metabolism, and brain development, the gut-brain axis has provided probiotic study a more detailed developmental framework. Because microbiota formation, immunological learning, stress axis calibration, and brain circuit growth all take place at the same time throughout infancy, this theory is specifically persuasive. SCFA-mediated signaling, vagal signaling, tryptophan and serotonin pathway control, systematic and neuroinflammation decline, impact on blood-brain barrier stability, and microglial stimulation are among the theoretical processes (Wang et al., 2023).

3.6.2 Preclinical and Experimental Evidence

There is a large no of preclinical evidence. Probiotic and prebiotic regularly improved spatial learning, working memory, recognition memory, and cognitive adaptability in mice, especially in models of early life stress or neuroinflammation, according to a 2025 cross-species organized review by Sal-Sarria and Burnet. Mechanistically, these effects were licked with better blood-brain barrier

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

stability, lower inflammatory signaling, and modulation of the hypothalamic-pituitary axis. However according to the same assessment, human newborn and pediatric study is still significantly less conclusive and far more heterogeneous (Wang & Xu, 2025).

3.6.3 Human Clinical Evidence and Follow-up studies

Thus, it is essential to convey human findings with warning. While studies with therapy duration longer than 6 months shown a slight positive trend, latest meta-analysis of randomized trials in infants and young children observed no overall significant advantages of probiotics on neurocognitive results. The current pediatric clinical proof is limited to strengthen routine probiotic usage for cognitive improvement, but it also emphasizes the possibility that any neurodevelopmental impacts may require extended interaction or may only manifest in particular populations (Panchal et al., 2023).

Neonatal subsequent studies are more targeted show the field's potential as well as its inconsistency. Kumar et al. (2024) observed that supplementing highly preterm children with *Limosilactobacillus reuteri* improved language scores but did not significantly alter broadly development or general neurodevelopment at two years. Equivalent long-term neurodevelopment and atopy-related results were detected in the later school-age follow-up comparing single strains and triple-strains bifidobacterial regimens are highly preterm children, demonstrating safety but not meaningful neurocognitive divergence among probiotic methods.

3.6.4 Current Interpretation and Future Perspective

This part will more rebuts for your evaluation if it is written as an emerging frontier instead of an established sign. Although the gut-brain axis provides a compelling molecular framework, there is still a significant translational gap between animal study and human newborn results. Both scientifically and analytically, this distinction is important (Tan-Lim et al., 2025).

3.7 HMOs and Synbiotics

3.7.1 Human Milk Oligosaccharides in Infant Gut Health

Human milk oligosaccharides (HMOs) are third biggest component of breast milk that plays a very supportive role in forming the infant gut microbiome. They act as specific substrates for beneficial microbes, inhibit pathogen bindings by operating as mimic receptors, and immediately impact the epithelial and immune growth. Their significance lies not only in feeding advantageous bacteria but also in forming a healthy microbial ecosystem similar to that seen in breastfed infants (Dinleyici et al., 2023). This microbiota-supporting effect is also associated with normal infant growth outcomes during early life, as further supported by findings in severely malnourished infants (Figure 2) (Nuzhat et al., 2023).

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593




Figure 2: Growth outcomes of infants receiving HMO-enriched synbiotic formula during the first year of life (Alliet et al., 2022).

3.7.2 HMO-Utilizing Bifidobacteria

Some microbial strains are widely accepted to use HMOs, especially Bifidobacterium longum subsp. infantis. These strains have particular genes that facilitate efficient HMO digestion and the formation of beneficial metabolites like acetate and aromatic lactic acids, which preserve the stability of the gut defense and immunological balance (Bakshani & Crouch, 2024). Such microbiome-associated benefits may contribute to healthy anthropometric development in infants receiving HMO-based formulations, figure 2. Integrating HMOs and HMO-specialized Bifidobacteria is biologically more effective than using either component alone because many traditional probiotic strains lack this flexibility (Button et al., 2022).

3.7.3 Evidence From HMO-enriched and Synbiotic Formulas

The benefits of HMO-fortified compositions are supported by clinical study. In addition to sustaining normal development and adaptability, a formula including lacto-N-neotetraose and 2'-fucosyllactose (2'-FL) reduced bronchitis episodes and the requirements for antibiotics and antipyretics. According to a various studies formula comprising *Lactobacillus reuteri* DSM 17938 + 2'-FL was safe and altered microbial profile to resemble those of breastfed babies, with fewer potential pathogens and increased level of Bifid bacteria, normal growth outcomes were mentioned throughout the study. In similar vein,2'-FL increased the bifidogenic impacts of the GOS/FOS-based formula compared to GOS/FOS alone (Puccio et al., 2017).

Frontier in Medical & Health Research
ISSN: (e) 3007-1607 (p) 3007-1593

3.7.4 Synbiotic Synergy

The probiotic strain's biological suitability with the prebiotic medium defines how effective synbiotics are. Random probiotic-prebiotic mixtures are probably less efficient than HMOs integrated with HMO-modified Bifidobacteria. Galacto-oligosaccharides may produce higher outcomes than less specific substrates, based on evidence from allergy-prevention trails, emphasizing the need of selecting the appropriate prebiotic and timing approach (Zhang et al., 2022).

3.7.5 Limits Compared with Breastfeeding

HMO-fortified and symbiotic formulas cannot entirely replace breast milk, despite their clear benefits. A dynamic blend of diverse HMOs, living microorganisms, immunological factors, enzymes, cytokines, and bioactive lipids can be identified in human milk. Therefore, this formulation is recommended to be seen as advantageous growth for newborn who are not breastfed, although they are only partial rather than whole substitutes for nursing (Thum et al., 2021).

3.8 Comparative Insights

3.8.1 Preterm versus Term Infants

Probiotic impacts on preterm and term infants are very different. The most evident clinical advantages are seen in preterm neonates due to their immature gut barrier and disrupted microbiota, especially in preventing necrotizing enterocolitis (NEC). Studies on healthy term infants, on the other hand, regularly concentrate on less intense consequences such colic, dermatitis stooling patterns, or microbiome modification. Because of this, the benefits of probiotics for term babies are usually less substantial and variable (Lazarini et al., 2025).

3.8.2 Distinct Roles of Probiotics, Prebiotics, synbiotics, and HMOs

Instead of being competing instruments, these therapies should be considered as supportive. Prebiotics specifically nourish beneficial bacteria, synbiotics unite both strategies, probiotics directly incorporate live microbes, and HMOs are a particular family of prebiotics with extra host advantages. While HMOs and synbiotics may be more meaningful for simulating breastfeeding-associated microbial activities in formula-fed newborns, probiotics are especially helpful in dysbiotic circumstances like preterm (Bosheva et al., 2022).

3.8.3 Importance of Strains Specificity

Rather than being universal, probiotics advantages are strains specific. The species, strain, dosage, duration, administration technique, and host condition all affect the outcomes. Because they colonize successfully, create pertinent metabolites, and are evolutionarily accepted to the milk-fed newborn gut, newborn-type bifidobacteria are particularly encouraging. For aliments like colic or acute diarrhea, different strains can be more suitable (Jochum et al., 2023).

3.8.4 Importance of strain Specificity

Enhancement is microbial diversity or abundance is frequently observed in trails with weak clinical outcomes. This is not an indicator of a failed course of treatment. Compared to uncomplicated bacterial counts, functional metrics containing metabolic generation, immunological regulation, and gut defense strength may have more robust association with health advantages. Metagenomics metabolomics, and long-term follow-up will be integrated in future research to more efficiently find significant biomarkers (Lasekan et al., 2022).

3.8.5 Future Direction: Precision Microbiota Therapy

Precision microbiota-directed therapy using the suitable strain, in the suitable newborn, at the relevant growth period, with the adequate substrate is the direction of future study. Stronger guidelines, product consistency, and prolonged safety fata are necessary for development (Picaud et al., 2025).

In the future, the field is potentially going to move away from broad compositions and towards a more personalized, hos-informed approach where strains screening is directed by an infant's genetic profile, birth mode, and baseline microbial signature. It may will respond best to a certain intervention before treatment starts by integrating

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

metagenomics, metabolomics, and immunological profiling. Verifying if early benefits persist over time will need long-term follow-up that goes beyond infancy and uniform reporting across trials. To guarantee that these precision-based approaches continue to be applicable worldwide, more representation of diverse and resource-constrained population will also be essential (Shin et al., 2025).

4. Conclusion

The results continuously show that early microbial colonization is highly regulated and clinically meaningful developmental process, and that, when applied in a strain-specific, context-adapted, and developmentally informed approach, microbiota-directed strategy represent a scientifically endorsed approach for optimizing infant health results. The prevention on necrotizing enter colitis (NEC) in premature infants is the most rigorous and well-documented clinical advantage of probiotic use in infancy. Beyond neonatal morbidity, perinatal probiotic supplementation shows meaningful reclines in atopic dermatitis and allergic sensitization, particularly with mixed-strain formulations initiated in the third trimester and continued postnatal. This review has multiple challenges. Considerable differences in probiotic strains, dosage, timing of administration, and the terminology used to characterize results among studies minimize the overall strength of the available findings and make immediate comparison between studies more difficult. The most emerging and empirically robust strategy to improving the clinical utility of probiotics and related bio therapeutics in early life is the shift toward precision micro biota-directed therapy, which involves selecting the right strain for the right infant at the right developmental window with the right substrate.

REFERENCES

Aceti, A., Gori, D., Barone, G., Callegari, M. L., Di Mauro, A., Fantini, M. P., Indrio, F., Maggio, L., Meneghin, F., Morelli, L., Zuccotti, G., & Corvaglia, L. (2015). Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. *Italian Journal of Pediatrics*, 41, 89. https://doi.org/10.1186/s13052-015-0199-2

Alliet, P., Vandenplas, Y., Roggero, P., Jespers, S. N. J., Peeters, S., Stalens, J. P., Kortman, G. A. M., Amico, M., Berger, B., Sprenger, N., Cercamondi, C. I., & Corsello, G. (2022). Safety and efficacy of a probiotic-containing infant formula supplemented with 2'-fucosyllactose: a double-blind randomized controlled trial. *Nutrition Journal*, 21(1). https://doi.org/10.1186/S12937-022-00764-2

Aveline, A., Szatkowski, L., Berrington, J., Costeloe, K., Ojha, S., Fleming, P., & Battersby, C. (2026). *Evaluating the effect of probiotics on severe necrotising enterocolitis in preterm infants born before 32 weeks gestation in England and Wales: a propensity-matched analysis. The Lancet Regional Health – Europe. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00363-1/fulltext*

Bakshani, R. A., & Crouch, L. *I. (2024). Human milk oligosaccharides and Bifidobacterium species. Trends in Microbiology. https://doi.org/10.1016/j.tim.2023.11.015*

Bogaert, D., van Beveren, G. J., de Koff, E. M., Lusarreta Parga, P., Balcazar Lopez, C. E., Koppensteiner, L., Clerc, M., Hasrat, R., Arp, K., Chu, M., de Groot, P. C. M., Sanders, E. A. M., van Houten, M. A., & de Steenhuijsen Piters, W. A. A. (2023). Mother-to-infant microbiota transmission and infant microbiota development across multiple body sites. *Cell Host & Microbe*, 31(3), 447–460. https://doi.org/10.1016/j.chom.2023.01.017

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Bosheva, M., Tokodi, I., Krasnow, A., Pedersen, H. K., Lukjancenko, O., Eklund, A. C., Grathwohl, D., Sprenger, N., Berger, B., & Cercamondi, C. I. (2022). Infant formula with a specific blend of five human milk oligosaccharides drives the gut microbiota development and improves gut maturation markers: a randomized controlled trial. *Frontiers in Nutrition*, 9, 920362. https://doi.org/10.3389/fnut.2022.920362

Brasiel, P. G. A., & Luquetti, S. C. P. D. (2025). Effects of probiotics supplementation on short-chain fatty acids: A systematic review of randomized controlled trials. *Nutrition Reviews*, 83(10), 1892–1907. https://doi.org/10.1093/nutrit/nuaf047

Button, J. E., Autran, C. A., Reens, A. L., Cosetta, C. M., Smriga, S., Ericson, M., Pierce, J. V., Cook, D. N., Lee, M. L., Sun, A. K., et al. (2022). Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. *Cell Host & Microbe*, 30(5), 712–725.e7. https://doi.org/10.1016/j.chom.2022.02.011

Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., & Kovatcheva-Datchary, P. (2015). Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host & Microbe*, 17(5), 690–703. https://doi.org/10.1016/j.chom.2015.04.004

Calvo, L. N., Greenberg, R. G., & Gray, K. D. (2024). Safety and effectiveness of probiotics in preterm infants with necrotizing enterocolitis. *NeoReviews*, 25(4), e193–e206. https://doi.org/10.1542/neo.25-4-e193

Dai, Y., Yu, Q., Zhang, F., Ma, K., Yan, X., Chen, W., Chen, X., Li, S., & Han, S. (2025). Effect of probiotics on necrotizing enterocolitis in preterm infants: a network meta-analysis of randomized controlled trials. *BMC Pediatrics*, 25, 220. https://doi.org/10.1186/s12887-025-05469-z

Davis, E. C., Castagna, V. P., Sela, D. A., Hillard, M. A., Lindberg, S., Mantis, N. J., et al. (2022). Gut microbiome and breast-feeding: implications for early immune development. *Journal of Allergy and Clinical Immunology*, 150(3), 523–534. https://doi.org/10.1016/j.jaci.2022.07.014

Dinleyici, M., Barbieur, J., Dinleyici, E. C., & Vandenplas, Y. (2023). Functional effects of human milk oligosaccharides (HMOs). *Gut Microbes*, 15(1), 2186115. https://doi.org/10.1080/19490976.2023.2186115

Ennis, D., Shmorak, S., Jantscher-Krenn, E., & Yassour, M. (2024). Longitudinal quantification of Bifidobacterium longum subsp. infantis reveals late colonization in the infant gut independent of maternal milk HMO composition. *Nature Communications*, 15(1), 894. https://doi.org/10.1038/s41467-024-45209-y

Feng, X., Li, L., Yan, L., Yan, Z., Xu, Z., Fan, Y., Madjirebaye, P., & Wu, X. (2025). Probiotics attenuate food allergy via short-chain fatty acids-mediated immune modulation and gut barrier restoration. *Foods*, 14(22), 3953. https://doi.org/10.3390/foods14223953

Fijan, S., Kolč, N., Hrašovec, M., Jamtvedt, G., Šikić Pogačar, M., Mičetić Turk, D., & Maver, U. (2023). Single-strain probiotic lactobacilli for the treatment of atopic dermatitis in children: a systematic review and meta-analysis. *Pharmaceutics*, 15(4), 1256. https://doi.org/10.3390/pharmaceutics15041256

He, P., Yu, L., Tian, F., Chen, W., Zhang, H., & Zhai, Q. (2024). Effects of probiotics on preterm infant gut microbiota across populations: a systematic review and meta-analysis. Advances in *Nutrition*. https://doi.org/10.1016/j.advnut.2024.100192

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Henrick, B. M., Rodriguez, L., Lakshmikanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., & Wang, J. (2021). Bifidobacteria-mediated immune system imprinting early in life. *Cell*, 184(15), 3884–3898. https://doi.org/10.1016/j.cell.2021.05.030

Ho, N. T., Li, F., Lee-Sarwar, K. A., Tun, H. M., Brown, B. P., Pannaraj, P. S., et al. (2018). Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations. *Nature Communications*, 9, 4169. https://doi.org/10.1038/s41467-018-06473-x

Hojsak, I., Dinleyici, E. C., van den Akker, C. H. P., Domellöf, M., Haiden, N., Szajewska, H., Vandenplas, Y., & ESPGHAN Special Interest Group on Gut Microbiota and Modifications. (2026). Technical review by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications on the health outcomes of infant formula supplemented with manufactured human milk oligosaccharides. *Journal of Pediatric Gastroenterology and Nutrition*, 82(1), 225–234. https://doi.org/10.1002/jpn3.70032

Husein-ElAhmed, H. (2023). Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. https://doi.org/10.1111/ddg.15120

Inchingolo, F., Inchingolo, A. M., Latini, G., Ferrante, L., de Ruvo, E., Campanelli, M., Longo, M., Palermo, A., Inchingolo, A. D., & Dipalma, G. (2024). Difference in the intestinal microbiota between breastfeed infants and infants fed with artificial milk: a systematic review. *Pathogens*, 13(7), 533. https://doi.org/10.3390/pathogens13070533

Indrio, F., Gutierrez Castrellon, P., Vandenplas, Y., Cagri Dinleyici, E., & Francavilla, R. (2022). Health effects of infant formula supplemented with probiotics or synbiotics in infants and toddlers: systematic review with network meta-analysis. *Nutrients*, 14(23), 5175. https://doi.org/10.3390/nu14235175

Jankiewicz, M., Łukasik, J., Kotowska, M., Kołodziej, M., & Szajewska, H. (2023). Strain-specificity of probiotics in pediatrics: a rapid review of the clinical evidence. *Journal of Pediatric Gastroenterology and Nutrition*, 76(2), 227–231. https://doi.org/10.1097/MPG.0000000000003675

Jochum, F., Meyer-Krott, M., Hübler, T., Lorenz, M., Bedikian, R., Zakarian, J., Litzka, A., Judex, G., Hertzberg, H., Klee, D., Maurer, L., Schacht, M., Al-Radhi, A., Maier, J., Kröckel, A., Faustmann, C., Lavalle, L., & Dahbane, S. (2023). Real-world evidence study on tolerance and growth in infants fed an infant formula with two human milk oligosaccharides vs mixed fed and exclusively breastfed infants. *Molecular and Cellular Pediatrics*, 10, 7. https://doi.org/10.1186/s40348-023-00162-6

Kiely, L. J., Busca, K., Lane, J. A., van Sinderen, D., & Hickey, R. M. (2023). Molecular strategies for the utilisation of human milk oligosaccharides by infant gut-associated bacteria. *FEMS Microbiology Reviews*, 47(6). https://doi.org/10.1093/femsre/fuad056

Kumar, A., Sivamaruthi, B. S., Dey, S., Kumar, Y., Malviya, R., Prajapati, B. G., & Chaiyasut, C. (2024). Probiotics as modulators of gut-brain axis for cognitive development. *Frontiers in Pharmacology*, 15, 1348297. https://doi.org/10.3389/fphar.2024.1348297

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Lasekan, J., Choe, Y., Dvoretskiy, S., Devitt, A., Zhang, S., Mackey, A., Wulf, K., Buck, R., Steele, C., Johnson, M., & Baggs, G. (2022). Growth and gastrointestinal tolerance in healthy term infants fed milk-based infant formula supplemented with five human milk oligosaccharides (HMOs): a randomized multicenter trial. *Nutrients*, 14(13), 2625. https://doi.org/10.3390/nu14132625

Laursen, M. F., Sakanaka, M., von Burg, N., Mörbe, U., Andersen, D., Moll, J. M., Pekmez, C. T., Rivollier, A., Michaelsen, K. F., Mølgaard, C., Lind, M. V., Dragsted, L. O., Katayama, T., Frandsen, H. L., Vinggaard, A. M., Bahl, M. I., Brix, S., Agace, W., & Licht, T. R. (2021). Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. *Nature Microbiology*, 6, 1367–1382. https://doi.org/10.1038/s41564-021-00970-4

Lazarini, T., Tonon, K., Araujo Filho, H. B., & Morais, M. B. (2025). Bifidogenic effect of 2′-fucosyllactose (2′-FL) on the gut microbiome of healthy formula-fed infants: a randomized clinical trial. *Nutrients*, 17(6), 973. https://doi.org/10.3390/nu17060973

Liu, Y., & Yang, H. (2023). Editorial: The origin and establishment process of gut microbiota in early life. *Frontiers in Microbiology*, 14, 1155660. https://doi.org/10.3389/fmicb.2023.1155660

Ma, G., Chen, Z., Li, Z., & Xiao, X. (2024). Unveiling the neonatal gut microbiota: Exploring the influence of delivery mode on early microbial colonization and intervention strategies. *Archives of Gynecology and Obstetrics*, 310(6), 2853–2861. https://doi.org/10.1007/s00404-024-07843-1

Maghsoumi-Norouzabad, L., Bagherzadeh-Karimi, A., Aliakbari Majd, S., Hosseini, L., & Shahi, F. (2025). The effects of prebiotic dietary fibers, probiotics, and synbiotics on gut permeability and immunity: A systematic review. *International Journal of Medical Sciences*, 50(8), 500–529. https://doi.org/10.30476/ijms.2024.102363.3525

Marano, G., Sfratta, G., Marzo, E. M., Cozzo, G., Abate, F., Traversi, G., Mazza, O., Capristo, E., Gaetani, E., & Mazza, M. (2025). The pediatric microbiota-gut-brain axis: Implications for neuropsychiatric development and intervention. *Children*, 12(11), 1561. https://doi.org/10.3390/children12111561

More, D., Shepard, C., More, C., & Mayol-Kreiser, S. (2021). The perinatal use of probiotics, prebiotics, and synbiotics for the primary prevention of allergic diseases in children: a systematic review. *Human Nutrition & Metabolism*, 26, 200134. https://doi.org/10.1016/j.hnm.2021.200134

Nuzhat, S., Hasan, S. M. T., Palit, P., Islam, M. R., Mahfuz, M., Islam, M. M., et al. (2023). Effects of probiotic and synbiotic supplementation on ponderal and linear growth in severely malnourished young infants in a randomized clinical trial. *Scientific Reports*, 13(1), 1845. https://doi.org/10.1038/s41598-023-29095-w

Panchal, H., Athalye-Jape, G., Rao, S., & Patole, S. (2023). Growth and neuro-developmental outcomes of probiotic supplemented preterm infants—a systematic review and meta-analysis. *European Journal of Clinical Nutrition*. *https://doi.org/10.1038/s41430-023-01270-2*

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Picaud, J.-C., Claris, O., Gil-Campos, M., Salamanca De La Cueva, I., Cornette, L., Alliet, P., Léké, A., Castanet, M., Piloquet, H., de Halleux, V., Mitanchez, D., Vandenplas, Y., Maton, P., Jochum, F., Olbertz, D., Negre Policarpo, S., Lavalle, L., Fumero, C., Rodriguez-Garcia, P., Moll, J. M., Silva-Zolezzi, I., Zemrani, B., Hays, N. P., Sprenger, N., & Miranda-Mallea, J. (2025). Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, *B. infantis* LMG11588, and *B. lactis* CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial. *Frontiers in Nutrition*, 12, 1628847. https://doi.org/10.3389/fnut.2025.1628847

Puccio, G., Alliet, P., Cajozzo, C., Janssens, E., Corsello, G., Sprenger, N., Wernimont, S., Egli, D., Gosoniu, L., & Steenhout, P. (2017). Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial. *Journal of Pediatric Gastroenterology and Nutrition*, 64(4), 624–631. https://doi.org/10.1097/MPG.0000000000001520

Sal-Sarria, S., & Burnet, P. W. J. (2025). Probiotics, prebiotics, and the gut-brain axis in early neurodevelopment: a cross-species review. *Behavioural Brain Research*, 495, 115789. https://doi.org/10.1016/j.bbr.2025.115789

Selma-Royo, M., Dubois, L., Manara, S., Armanini, F., Cabrera-Rubio, R., Valles-Colomer, M., et al. (2024). Birth mode and environment-dependent microbiota transmission dynamics are complemented by breastfeeding during the first year. *Cell Host & Microbe*, 32(6), 996–1010.e4. https://doi.org/10.1016/j.chom.2024.05.005

Sharif, S., Meader, N., Oddie, S. J., Rojas-Reyes, M. X., & McGuire, W. (2023). Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. *Cochrane Database of Systematic Reviews*, 7(7), CD005496. https://doi.org/10.1002/14651858.CD005496.pub6

Shin, M. K., Son, Y., Yon, D. K., & Lee, J. (2025). Potential gut-brain axis-targeted therapies for autism spectrum disorder in children: Opportunities and challenges. *World Journal of Pediatrics*, 21(5), 447–467. https://doi.org/10.1007/s12519-025-00924-4

Sjælland, M., Philipsen, M., & Thysen, A. H. *(2025). Probiotics in term infants: clinical impact of infant-type bifidobacteria – a systematic review and meta-analyses. Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2025.114*

Suárez-Martínez, C., Santaella-Pascual, M., Yagüe-Guirao, G., & Martínez-Graciá, C. (2023). Infant gut microbiota colonization: influence of prenatal and postnatal factors, focusing on diet. *Frontiers in Microbiology*, 14, 1236254. https://doi.org/10.3389/fmicb.2023.1236254

Szajewska, H., Berni Canani, R., Domellöf, M., Guarino, A., Hojsak, I., Indrio, F., Lo Vecchio, A., Mihatsch, W. A., Mosca, A., Orel, R., Salvatore, S., Shamir, R., van den Akker, C. H. P., van Goudoever, J. B., Vandenplas, Y., & Weizman, Z. (2023). Probiotics for the management of pediatric gastrointestinal disorders: position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. *Journal of Pediatric Gastroenterology and Nutrition*, 76(2), 232–247. https://doi.org/10.1097/MPG.0000000000003633

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Talat, A., et al. (2025). *Unravelling the Gut-Microbiome-Brain Axis: Implications for Infant Neurodevelopment and Future Therapeutics. Current Microbiology.* *https://doi.org/10.1007/s00284-025-04370-3*

Tan-Lim, C. S. C., Esteban-Ipac, N. A. R., et al. (2025). Systematic review and meta-analysis on probiotics as treatment for food allergies among pediatric patients: a 2024 update. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70028

Tanaka, M., & Nakayama, J. (2017). Development of the gut microbiota in infancy and its impact on health in later life. *Allergology International*, 66(4), 515–522. https://doi.org/10.1016/j.alit.2017.07.010

Tarracchini, C., Milani, C., Lugli, G. A., Mancabelli, L., Turroni, F., van Sinderen, D., & Ventura, M. (2024). The infant gut microbiota as the cornerstone for future gastrointestinal health. *Advances in Applied Microbiology*, 126, 93–119. https://doi.org/10.1016/bs.aambs.2024.02.001

Thum, C., Wall, C. R., Weiss, G. A., Wang, W., Szeto, I. M. Y., & Day, L. (2021). Changes in HMO concentrations throughout lactation: Influencing factors, health effects and opportunities. *Nutrients*, 13(7), 2272. https://doi.org/10.3390/nu13072272 van den Akker, C. H. P., van Goudoever, J. B., Shamir, R., Domellöf, M., Embleton, N. D., Hojsak, I., et al. (2020). Probiotics and preterm infants: a position paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the ESPGHAN Working Group for Probiotics and Prebiotics. Journal of Pediatric Gastroenterology and Nutrition, 70(5), 664–680. https://doi.org/10.1097/MPG.0000000000002655

Vaz, S. R., Tofoli, M. H., Avelino, M. A. G., & da Costa, P. S. S. (2024). Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review. *Acta Paediatrica*, 113(2), 170–182. https://doi.org/10.1111/apa.17036

Wang, F., Wu, F., Chen, H., & Tang, B. (2023). The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta-analysis. *Translational Pediatrics*, 12(4), 731–748. https://doi.org/10.21037/tp-23-200

Wang, H. Z., Hayles, E. H., Fiander, M., Sinn, J. K. H., & Osborn, D. A. (2025). Probiotics in infants for prevention of allergic disease. *Cochrane Database of Systematic Reviews*, 6(6), CD006475. https://doi.org/10.1002/14651858.CD006475.pub3

Wang, L., & Xu, L. (2025). The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis. *Frontiers in Pediatrics*, 13, 1498965. https://doi.org/10.3389/fped.2025.1498965

Wang, M., Valizadegan, N., Fields, C. J., & Donovan, S. M. (2025). Fecal microbiome and metabolomic profiles of mixed-fed infants are more similar to formula-fed than breastfed infants. *Microorganisms*, 13(1), 166. https://doi.org/10.3390/microorganisms13010166

Wang, Y., Florez, I. D., Morgan, R. L., Foroutan, F., Chang, Y., Crandon, H. N., Zeraatkar, D., Bala, M. M., Mao, R. Q., & Tao, B. (2023). Probiotics, prebiotics, lactoferrin, and combination products for prevention of mortality and morbidity in preterm infants: a systematic review and network meta-analysis. *JAMA Pediatrics*, 177(11), 1158–1167. https://doi.org/10.1001/jamapediatrics.2023.3849

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Xiao, Z., Luo, H., Liu, H., Chen, H., Bai, J., Liao, W., Wen, S. W., Krewski, D., Shang, H., & Xie, R. (2025). Probiotic supplementation during pregnancy or infancy for the prevention of allergic rhinitis in infants: a systematic review and meta-analysis of randomized controlled trials. *World Allergy Organization Journal*, 18, 101124. https://doi.org/10.1016/j.waojou.2025.101124

Zhang, B., Li, L. Q., Liu, F., & Wu, J. Y. (2022). Human milk oligosaccharides and infant gut microbiota: molecular structures, utilization strategies and immune function. *Carbohydrate Polymers*, 276, 118738. https://doi.org/10.1016/j.carbpol.2021.118738

Zhou, K.-Z., Wu, K., Deng, L.-X., Hu, M., Luo, Y.-X., & Zhang, L.-Y. (2023). Probiotics to prevent necrotizing enterocolitis in very low birth weight infants: a network meta-analysis. *Frontiers in Pediatrics*, 11, 1095368. https://doi.org/10.3389/fped.2023.1095368